Evidence map›Paper›PMID 32536574›Full record

ArticleEuropean urology oncology2021

Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.

Matthew P Deek, Kekoa Taparra, Ryan Phillips, Pedro Isaacsson Velho, Robert W Gao, Curtiland Deville, Daniel Y Song, Stephen Greco, Michael Carducci, Mario Eisenberger and 9 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07691697 (Outcomes After PSMA PET-Guided Progression-Directed Radiotherapy, Including SBRT and Brachytherapy, for Oligoprogressive Prostate Cancer), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07691697 recruitingnot on this mapstarted 2026, after this paper: background citation

Outcomes After PSMA PET-Guided Progression-Directed Radiotherapy, Including SBRT and Brachytherapy, for Oligoprogressive Prostate Cancer: An Ambispective Multicenter Real-World Evidence Cohort Study

Typeobservational_patient_registrySponsorAffidea Nu-med Center of Oncological DIagnostics and TherapyRan2026 to 2031Enrolled1,000ConditionsOligoprogressive Prostate Cancer, Metastatic Prostate CancerArmsProgression-Directed Radiotherapy
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Matthew P DeekDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kekoa TaparraDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Ryan PhillipsDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pedro Isaacsson VelhoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert W GaoDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Curtiland DevilleDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel Y SongDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Stephen GrecoDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael CarducciDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mario EisenbergerDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Theodore L DeWeeseDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Samuel DenmeadeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kenneth PientaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Channing J PallerDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Emmanuel S AntonarakisDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kenneth R OlivierDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Sean S ParkDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Phuoc T TranDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Bradley J StishDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: Stish.Bradley@mayo.edu.
Johns Hopkins University · USMayo Clinic in Arizona · US

Funding

Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse modelU01CA231776 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANN, CHRISTINE L., MARCHIONNI, LUIGI · 2018 to 2022
$3.9M
Integrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABRR01CA200551 · NCI · MAYO CLINIC ROCHESTER · PI DONG, HAIDONG, PARK, SEAN S · 2016 to 2018
$739k
A pre-clinical x-ray/optical tomography-guided radiation research platform for pancreatic cancerR21CA223403 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TRAN, PHUOC T., WANG, KEN KANG-HSIN · 2018 to 2019
$386k
NCI NIH HHS R01 CA200551NCI NIH HHS R21 CA223403NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA231776
6 · The paper itself

Abstract

backgroundAvailable therapies for castrate-resistant prostate cancer (CRPC) confer minimal survival advantage; thus, there is interest in metastasis-directed therapy (MDT) for oligometastatic or oligoprogressive disease to improve outcomes. Here, we describe outcomes of oligoprogressive CRPC treated with stereotactic ablative radiotherapy (SABR).

objectiveTo report outcomes of oligoprogressive CRPC treated with MDT using SABR. DESIGN, SETTING, AND

participantsPatients with oligoprogressive CRPC were retrospectively evaluated, and outcomes following MDT were reported. Outcomes were additionally compared with oligoprogressive CRPC treated with change in systemic therapy alone.

interventionSABR to oligoprogressive lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes of interest were time to prostate-specific antigen (PSA) failure, time to next intervention (TTNI), distant metastasis-free survival (DMFS), and overall survival. Survival analysis was performed using the Kaplan-Meier method, and univariable analysis and multivariable analysis (MVA) were performed. RESULTS AND LIMITATIONS: A total of 68 patients were included. After MDT, median time to PSA recurrence, TTNI, and DMFS were 9.7, 15.6, and 10.8 months, respectively. A total of 112 lesions were treated, and the cumulative incidences of local failure at 12 and 24 months were 2.1% and 13.8%, respectively. Factors associated with the risk of local recurrence on univariable analysis were age (hazard ratio [HR] 1.07, p =  0.03) and Gleason grade group (HR 2.20, p =  0.07). Compared with change in systemic therapy alone (n = 52), MDT (n = 31) was associated with improved median time to PSA failure (9.7 vs 4.2 months, p =  0.066)), TTNI (14.9 vs 8.8 months, p =  0.025), and DMFS (12.7 vs 8.9 months, p = 0.045), and remained associated with improved outcomes on MVA.

conclusionsIn a retrospective cohort of oligoprogressive CRPC patients, MDT was associated with favorable outcomes and improved cancer control as compared with change in systemic treatment alone. Future prospective trials are needed to confirm these findings. PATIENT SUMMARY: In this report, we retrospectively analyzed outcomes of patients with oligoprogressive castrate-resistant prostate cancer treated with radiation therapy to progressing lesions. Our results suggest that treatment of these lesions with radiation therapy can result in sustained periods of disease-free survival and might add benefit in addition to systemic therapy at the time of progression. These results need to be verified in a prospective trial to identify the optimal integration of radiation therapy into metastatic castrate-resistant prostate cancer.

Indexed as

Prostatic Neoplasms, Castration-ResistantRadiosurgeryHumansMaleProgression-Free SurvivalProstate-Specific AntigenRetrospective StudiesProstate-Specific AntigenCastrate-resistant prostate cancerMetastasis-directed therapyOligoprogressive

Identifiers

PMID32536574
PMCPMC7788526
OpenAlexW3034430250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.